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Abstract
More than one in six Americans will have a diagnosis of a substance use disorder at some time in
their life. According to the National Institute on Drug Abuse (2020), those with a substance use
disorder will have an increased rate of having a comorbidity of depression or depression
symptoms during treatment, leading to poorer outcomes. The purpose of this quality
improvement project was to increase provider and staff adherence to the treatment standards
outlined in the Veteran’s Affair/Department of Defense Clinical Practice Guideline for the
Management of Major Depressive Disorder (Veteran’s Affairs/Department of Defense, 2016).
During this 10-week process, providers and staff were educated on the guidelines and were able
to put what they learned into practice. Patients who were 18 years of age and older were screened
upon admission to the addiction center for depression using the patient health questionnaire
screening tools two and nine for depression. Patients were given treatment by providers and staff
based on the Clinical Practice Guidelines. Treatment involved group cognitive behavioral
therapy with or without a serotonin reuptake inhibitor, and education on depression. Some
patients had another depression screening performed prior to discharge if applicable. Throughout
this project, 100% of staff were educated on the guidelines, and 42 patients were screened for
depression. Of the 42 screened, 69% had indications for treatment of depression or depression
symptoms. Treating these patients’ depression increased the likelihood of improving outcomes
after recovery. It is important to use current practice guidelines in addiction healthcare facilities
to help improve patient outcomes for substance.
Keywords: patient health questionnaire 9, addiction, depression, substance use disorder,
patient health questionnaire 2, depression screening
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Depression screening upon admission at an addiction facility:
A quality improvement project
It is estimated that more than 18% of Americans will experience a substance use disorder
(SUD) at some period in their life (Gabbard, 2014). Of these, 43% will have a comorbidity of a
depression diagnosis or symptoms of depression during treatment (National Institute on Drug
Abuse [NIDA], 2020). Patients with depression can have symptoms of worthlessness, lack of
energy, and poor concentration (Gabbard, 2014). These symptoms can impede recovery, leading
to poor outcomes. The risk of suicide also increases with patients that have depressive
symptoms, but if depression is not assessed, these symptoms may be overlooked. Compared to
patients suffering from either addiction or depression alone, those with both addiction and
depression are prone to have a more intense and prolonged clinical course of treatment with less
successful outcomes. Therefore, current practice guidelines endorse treating these co-occurring
disorders at the same time (Vujanovic et al., 2017).
Current Guidelines
The Veterans Affairs & Department of Defense clinical practice guideline for the
management of major depressive disorder (VA/DOD, 2016) calls for routine screening for
depression and suicide in adults suspected of depression admitted within the facility. The
guidelines recommend that all patients not currently receiving treatment for depression be
screened for depression using the patient health questionnaire-2 (PHQ–2 ). Once depression is
suspected the VA/DoD (2016) clinical practice guidelines recommend an acute safety risk
assessment, a detailed depression assessment by the provider, and the use of the patient health
questionnaire-9 as a quantitative measure of depression severity in the initial treatment planning
and to monitor treatment progress.
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Once depression is identified, the Substance Abuse and Mental Health Services
Administration (SAMHSA) treatment improvement protocol recommends that psychotherapies
like cognitive behavioral therapy or group cognitive behavioral therapy with or without
antidepressant adjunct use be implemented to effectively lower the frequency of substance use
and depressive symptoms ( SAMHSA, 2020). This improves the functionality of the patient in
the short term as well as in the long term. The VA/DoD (2016) clinical practice guidelines
recommend similar interventions based on the PHQ–9 scores of patients. If cognitive behavioral
therapy or group cognitive behavioral therapy is used with antidepressant adjunct they specify
the use of a serotonin reuptake inhibitor as the first choice for antidepressant use.
Statement of the Problem
During a microsystem assessment of the addiction facility, it was determined that
patients’ suicidal risk was being evaluated on admission. However, patients were not being
screened for depression. A retrospective chart review of the electronic health record admitting
assessment provided detailed questions of substance use disorders that patient would answer.
Patient were also asked of history of mental illness, medical history, social support,
environmental risk factors as well as an excerpt for suicidality. Patients who had a history of
depression and suicidal ideation in the past did not receive any additional screening for current
level of depression. Patients would report to staff on admission of having no support system,
environmental risk factors like social isolation, feelings of hopelessness/helplessness yet did not
receive a depression assessment or treatment for these symptoms of depression. Substance use
disorders co-occur at high prevalence rates with mental disorders, such as depression (NIDA,
2020). With this in mind, active depression tools upon admission will need to be in place.
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Background and Significance
While the SAMHSA treatment improvement protocol states there is no single assessment
tool gold standard for identifying co-occurring disorders, there are traditional clinical tools that
focus narrowly on specific problems (SAMHSA, 2020). The VA/DoD (2016) clinical practice
guidelines state that when a patient is suspected of having depression, an assessment of acute
safety risk should be implemented.
The VA/DoD recommends the use of the patient health questionnaire-9 (PHQ–9 ) as a
quantitative measure of depression for those diagnosed with major depressive disorder in the
initial treatment planning and ongoing monitoring of treatment progress prior to discharge.
Substance use may lead to changes in roughly some of the same areas in the brain that are
disrupted in other mental health disorders, like depression (NIDA, 2020). The PHQ–9 is a
validated tool that evaluates depressive symptoms and suicidal ideation. It can be added to the
treatment plan as a continuous means to assess depression severity and observe treatment
response. The PHQ–9 can also be used to observe patients’ responses after the start of treatment
when a change in treatment plans occurs and monthly until the depressive state has gone into
remission. The PHQ–9 defines remission as a score of four or less maintained for a minimum of
1 month. Once remission is obtained, the VA/DoD (2016) clinical practice guidelines
recommend that assessment for depression symptoms be continued periodically to monitor for
relapse or recurrence. The PHQ–9 has been proven to be an effective, brief, cost-effective scale
in identifying depression compared to other depression assessment tools (Dum et al., 2008).
Before a patient at the facility is given the PHQ–9 . They will need to score a positive
score on the patient health questionnaire-2 (PHQ–2 ). The PHQ–2 make up the first two items
on the PHQ–9 and is used to identify suspected depression. A score of three or higher on the
PHQ–2 make up positive score (Bentley et al., 2021).
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New SUD patients admitted to an inpatient addiction are put in a new environment where
to get better they must abstain drug use. Patients going through the change of not being able to
do the substance they were once able to do so frequently can cause a significant amount of stress
of which they had not yet learned to cope through. Increase stress is a known risk factor
depression and can cause poor motivation (NIDA, 2018). To prevent this, the PHQ
administration process following the VA/DoD clinical practice guidelines (2016) will need to be
applied. Once depression is identified, the SAMHSA (2020) treatment improvement protocol
recommends that psychotherapies like cognitive behavioral therapy or group cognitive
behavioral therapy with or without antidepressant adjunct use be implemented to effectively
lower the frequency of substance use and depressive symptoms. This improves functionality of
the patient in the short term as well as in the long term. The VA/DoD clinical practice guidelines
(2016) recommend similar interventions based on the PHQ–9 scores of patients.
Assessment
I completed an assessment of an addiction care facility located in a large urban city in the
southern United States. The assessment took place in the fall of 2020 over a 3 month period
following the clinical microsystems format of the Dartmouth Institute Microsystem Academy
(2005).
Physical Structures
The addiction recovery facility encompasses three units: an intensive outpatient unit with
a total of 32 beds, a residential unit with a total of 20 beds, and a transitional living unit with a
total 20 beds. For purposes of this project the assessment focused on the residential unit, as this
was where the project interventions took place. The facility consists of multiple buildings
including a check-in building, a medical building, a kitchen/dining building, multiple lodging
buildings, as well as therapy and recreational buildings. Aside from the medical building, each
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building was 30 ft by 40 ft in estimated room size. The patient check-in building staffed with two
mental health workers (MHW) and had a waiting room that accommodates 10 clients at a time.
Due to the novel coronavirus (COVID19) pandemic patients had to call ahead and set up an
appointment for when to come in. Once patients checked in, they were escorted to the medical
building. The medical building was always staffed by two registered nurses. The medical
building includes two patient examination rooms where providers assessed patients as well as, a
provider’s office in the corner of the building, one restroom, two patient rooms where intense
acute detoxification could be managed, a medication kiosk where patients could take scheduled
or as needed medications, an area for laboratory test processing, a supplies area, and a
medication storage area. The kitchen/dining area consisted of 20 sitting areas for patients’ dishes,
and silverware that could accommodate 30 people at one time as well as a fruit station, a fountain
drink dispenser, and a break room for staff. The residential hall is the only unit where patients
are an inpatient in the facility. This means it is closest to most of the amenities in the addiction
facility. The residential area consists of a recreational building where patients can exercise with
free weights or run on the treadmill. The residential area contains 10 separate patient buildings,
which holds up to two patients each. Inside each patient building is a day area with a small
kitchen for a patient to put personal snacks as well as a microwave; there is also a bedroom
which has two beds inside, and a bathroom with a sink, toilet, and a shower inside. The
residential area is closest to the medical building where the phone area resides; patients could
call outside of the facility to friends and family at certain times during the day. The residential
hall is also the closest to the building used for group and individual therapy.
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Purpose of Facility
The addiction recovery facility offers a unique approach to addiction treatment that helps
patients achieve lasting recovery. The facility does not have a formal mission statement; but does
offer collaborative addiction treatments for alcohol and drug rehabilitation.
Patients
The residential unit can accommodate up to 20 patients at a time. Patients can be male or
female, and must be 18 years or older and diagnosed with an SUD to qualify for admission. If a
patient identifies as transgender and meets other requirements for admission, the clinic
accommodates by giving the patient their room without a roommate. Patients see a provider
daily, and the type of healthcare professional that supervises the unit varies depending on the
day. At the time of the assessment, there were a total of 13 patients at the residential unit.
Representing the majority of patients, were nine men. Eight of the men were white and between
the ages of 36 and 46 years. The remaining patient's age was 25 to 35 years. The last male was
Black and fell into the age range of 47 to 57 years. There were four female patients at that time;
three were females between 25 to 35 years of age, and one fell into the age range of 18 to 24
years. All females during this time were white. There were no patients during the assessment
phase who identified as transgender. 13 SUD patients during the assessment phase only one was
diagnosed and being treated for depression.
Professionals
The addiction recovery facility employed or contracted with one psychiatrist, two
psychiatric mental health nurse practitioners (PMHNP), six registered nurses (RNs), eight
MHWs, one addiction therapist, two cognitive-behavioral therapists, five counselors, two
counselor intern students, and two case managers. The role of the RNs was to provide nursing
care for patients including assessing patients, reporting uncommon findings to the provider;
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completing intakes and admission assessment paperwork, administering medications, and
documenting on all of the patients; and answering any patient questions within the RNs scope of
practice. The RNs collected ordered lab specimens, and assisted providers during telehealth visits
as required. The RN staff was assigned specific weekdays and, weekend shifts that were 12
hours in length either from 7:00 a.m. to 7:00 p.m. or 7:00 p.m. to 7:00 a.m. There was also a
small number of as needed RNs that were assigned 12-hour shifts based on needs of the facility.
There were three or four MHWs assigned to the day shift from 7:00 a.m. to 7:00 p.m. and
two or three MHWs assigned to the night shift from 7:00 p.m. to 7:00 a.m. based on patient
census. The MHWs role varies each shift. MHWs might be assigned to the patient check in
building, assigned to completing office duties like scheduling a patient visit, assigned to assist
the therapists or counselors in group sessions, assigned to setup patients’ rooms, or escort
patients to planned activities outside of the facility.
The psychiatrist and the PMHNPs would perform new evaluations on new patients and
daily assessments on progress with patients. These providers would use information gathered
during intake as a primary focus on what the initial evaluation would be focused on. The
providers were able to prescribe medications they see fit to progress patient to a more favorable
outcome. At least one provider would work a day, and alternate shifts dependent on the day. The
PMHNPs are both doctorly prepared, and one is dual certified as a family nurse practitioner
(FNP) as well. The dual certified nurse practitioner assesses a patient need for medical
intervention upon patients request and when need arises.
The addiction therapist, cognitive-behavioral therapists, and counselors work in
collaboration to bring needed individual or group therapy care to patients. The intern students
work primarily with a counselor and sometimes hold group counseling sessions for patients.
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Case managers primarily work with patients for aftercare setup. This means during their stay the
case manager is looking for possible placement in either a group home or discharge to home with
the right resources to get in contact with a sponsor and a suitable outpatient facility.
Recovery Processes
The average length of stay in the facility for a residential patient is 30 days. Patients are
admitted on a voluntary basis and can choose to leave treatment at any time. A typical patient
visit starts with the check in process that is conducted in the check in building. The patient is
greeted by an MHW and an administrative staff member to go over what is expected while at the
facility. Patients belonging are inspected for contraband. If any contraband is found patients are
told to give the contraband to their family members or the contraband is placed in a safe until the
patient is discharged. Patients are then escorted to the medical building by the MHW where
patients are met by the RN.
Once the RN assumes care of the patient, vital signs are obtained as well as a complete
intake and admission assessment performed. The RN also obtains a urine drug screen from the
patient. Random urine drug screens are also performed throughout the patient’s stay. Most of the
patient information obtained by the RN is recorded in the electronic health record (EHR).
However, there is some paperwork that requires the patient to complete a paper document
including a suicide screening tool and a fall risk questionnaire. Once the patient completes these
documents the RN scans the completed papers into the EHR. Once the patient’s intake process is
completed, the patient is escorted to the residential unit to settle in.
Patient records are accessible through the EHR system. The current EHR system is
accessible by all of the professional staff. EHR access includes clinical progress notes, group
session notes, patients’ schedules, financial intake information, patients’ medical intake
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information, current issues related to recovery, treatment plans, laboratory results including drug
screens, appointments, discharge planning notes. Paper charting is not used in this facility.
Throughout patients’ stays, they have daily visits with their provider, attend voluntary
alcoholic anonymous or narcotic anonymous meetings on the weekends, attend group therapy
sessions twice a day, meet with their individual counselors, and take their prescribed medication
regimen. Additionally, patients also participate in recreational activities such as yoga and
meditation.
Despite having a structured itinerary, patients had approximately a 2 hr period of free
time during the day. This time was used by the patients to participate in recreational activities,
ask for as needed medications, or use the telephone. I also noted that although cognitive
behavioral therapy and counseling was voluntary, the majority of patients attended every session.
Patterns and Need for an Intervention
The microsystem assessment revealed that patients’ suicidal risk was being evaluated but
patients’ depression risk was not being addressed despite the VA/DoD (2016) clinical practice
guidelines indicating the need to assess for both. As previously described, the facility was able to
readily access suicide risk in the form of a questionnaire that was completed by the patient
during the intake and admitting assessment process. The completed suicide risk form was
scanned into the patient’s EHR. This indicated that it was possible to implement other risk
assessment tools and scan those documents into the EHR. Providers are able to easily access all
scanned documentation in the EHR before interacting with the patient.
The facility had weekly interdisciplinary team meetings with at least one person from
each profession in attendance to discuss active patients in the facility. Patient privacy is
maintained during these meetings; however, any patient identified as being at risk for suicide
was discussed by the team. Even though this information was readily available in the EHR, it
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was important for the team to discuss all notable information to reduce patients’ suicide risk. I
was able to determine that assessing patients’ depression risk and discussing these risks in the
interdisciplinary team meetings would not have a significant impact on the facility routine,
would help the facility be in compliance with current clinical practice guidelines, and could have
a substantial impact on patient outcomes.
Readiness for Change
After I completed my assessment of the facility, I met with administrators, the chief
executive officer (CEO), providers and other staff to discuss my findings. I highlighted that the
facility was not currently meeting the VA/DoD (2016) clinical practice guideline and suggested
implementing the use of the PHQ–9 to assess for depression risk at admission, every 30 days,
and prior to discharge. The CEO and providers were quite familiar with the PHQ–9 assessment
tool and had no qualms with the proposed intervention. After a brief discussion with the staff
about the VA/DoD clinical practice guidelines, the staff was eager to learn more and were
inquisitive about when the proposed implementation would begin. The CEO was more than
happy to give letter of support as shown in Appendix A (See Appendix A).
Project Identification
Purpose
The purpose of this quality improvement (QI) project was to increase adherence to the
VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder
(VA/DOD, 2016) for adults admitted to an inpatient addition recovery facility.
Objectives
1. Educate 100% of providers working within the addiction recovery facility on the
screening and treatment standards outlined in the VA/DoD Clinical Practice Guideline for
the Management of Major Depressive Disorder (VA/DOD, 2016).
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2. Educate 100% of staff on the proper screening for depression and suicidal ideation of
adult patients admitted to the addiction recovery facility using the PHQ–9 as outlined in
the VA/DoD Clinical Practice Guideline for the Management of Major Depressive
Disorder (VA/DOD, 2016).
3. 100% of individuals who score positive on the patient health questionnaire-2 (PHQ–2 )
will complete the PHQ–9 .
4. Increase the percentage of adult patients screened for depression and suicidal ideation
upon admission to the addiction recovery facility with the PHQ–9 from the preintervention rate of 0% to 95% by the completion of the project implementation period.
5. Increase provider adherence rate to the treatment standards outlined in the VA/DoD
Clinical Practice Guideline for the Management of Major Depressive Disorder (VA/DOD,
2016) for patients who have a positive score (> 4) on the PHQ–9 from 0% to 95% by the
completion of the project implementation period.
6. Increase the PHQ–9 periodic reassessment rate at least every 30 days or sooner if
discharge before 30 days as outlined in the VA/DoD Clinical Practice Guideline for the
Management of Major Depressive Disorder (VA/DOD, 2016) of patients within the
addiction recovery facility from 0% to 95% by the completion of the project
implementation period.
Anticipated Outcomes
1. 100% of providers will be educated on proper usage of the PHQ–9 by the completion of
the project implementation period
2. 100% of staff will be educated on proper usage of the PHQ–9 by the completion of the
project implementation period
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3. 100% of individuals who score positive on the PHQ–2 will complete the PHQ–9
4. 100% of the completed PHQ–2 scores will be scanned and documented into the facility’s
EHR system
5. 100% of the completed PHQ–9 scores will be scanned and documented into the facility’s
EHR system
6. Providers will adhere to the treatment standards outlined in the VA/DoD Clinical Practice
Guideline for the Management of Major Depressive Disorder (VA/DOD, 2016) at least
95% of the time.
7. Assembly with providers and staff to recognize and address possible barriers to 95%
completion rate
Summary and Strength of the Evidence
Literature used for evidence in the project was found using PubMed, Medline, Cochrane
Library, and CINAHL. Quality of evidence was measured using the John Hopkins Nursing
Evidence-Based Practice scale described by Dang & Dearholt (2018). Multiple articles ranged
used in this project ranged from level I evidence like from systematic reviews and meta-analysis
of randomized controlled studies to level VII evidence like the expert opinion of authorities
and/or reports of expert committees. Articles included had to have evidence regarding screening
tools that can be used for SUD patients that have a comorbidity of depression or are actively
being treated concurrently for SUD and major depressive disorder (MDD). Unlike individuals
experiencing either disorder alone, individuals having both disorders are more likely to undergo
a severe and chronic display of clinical symptoms with far worse treatment outcomes. Thus,
current practice guidelines recommend treating these co-occurring disorders simultaneously.
(SAMHSA, 2020; Stein et al., 2017; Vujanovic et al., 2017). There is no single gold standard
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assessment tool for co-occurring SUD and MDD. Instead, the traditional clinical tools that focus
narrowly on a single problem are most commonly used (SAMHSA, 2020).
PHQ–2
The PHQ–2 has been used in studies and shown to be an effective screening tool for
depression in patients with a substance use disorder (Stein et al., 2017; Bryan et al., 2021).
However, it was found that the PHQ–2 in conjunction with the PHQ–9 showed far better
accuracy than the PHQ–2 alone. Levis et al. (2020) conducted a meta-analysis that included a
total of 10627 participants from 44 studies to evaluate the accuracy of the PHQ–2 alone and in
combination with the PHQ–9 for screening to detect major depression. The study showed that
the PHQ-2 had less specificity than the use of PHQ–2 and PHQ–9. The PHQ–2 followed by the
PHQ–9 for applicable patients may be the ideal approach, as it shows higher sensitivity or
specificity than the PHQ–2 alone. The PHQ–2 is made up of the first two items in the PHQ–9
which measure depressed mood and anhedonia. Items on the questionnaire use a Likert scale that
rates from 0 (not at all) to 3 (nearly every day). The lowest score an individual can have on this
tool is 0 and the highest is 0. A score of 3 or greater is considered a positive score (Bentley et al.,
2021). This can be used as the first step in identifying for depression evaluation with the entire
PHQ–9 .
PHQ–9
Dum et al. (2008) conducted a cross-sectional study on 108 SUD patients in a treatment
center to evaluate the psychometric properties of the Beck Depression Inventory-II (BDI–II) and
the PHQ–9 with alcohol and drug abusers. The study showed that the BDI–II and PHQ–9
depression scales had good psychometric properties and were similarly correlated with SUD
severity levels. It was notable that the PHQ–9 was faster and free to use for providers. Both
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scales were equally recommended for use with individuals with substance abuse disorders (Dum
et al., 2008).
Delgadillo et al. (2011) conducted a validation study on 103 patients with SUD to test the
reliability and validity in this population. This study brought positive results as it showed the
PHQ–9 to be a valid and reliable tool for this population. Emphasizing the ease of
administration and how brief it took to fill out, made it a useful clinical tool (Delgadillo et al.,
2011).
The 9-item PHQ–9 assesses the frequency of depressive symptoms in the past 2 weeks.
Like the PHQ–2 , it uses a Likert scale that rates from 0 (not at all) to 3 (nearly every day).
Scores range from 0 to 27, a score of 5 or higher may warrant intervention and retest in a month
(MacArthur Initiative on Depression & Primary Care, 2009). Interventions of psychotherapy or
antidepressant usage are warranted with a score greater than 10. The PHQ–9 is a public domain
measure and can be freely downloaded without the worry of copyright issues (Kroenke, 2017).
Screening tools are a necessity and exceptionally important when treating an illness. Benefits for
the usage of the PHQ–9 for depression screening have been shown for initial and ongoing usage
throughout care (American Psychiatric Association, 2016; Arbuckle et al., 2013; VA/DOD,
2016).
Cognitive Behavioral Therapy
Traditional Cognitive Behavioral Therapy (CBT) approaches for the treatment of SUD
depression are well-studied and have been shown to be the preferred treatment of choice
(Vujanovic et al., 2017). Individuals in CBT will learn to identify and adjust problematic
behaviors by using a range of different skills which can be applied to stop drug abuse as well as
address a range of additional issues that often co-occur with it (NIDA, 2018). A key point in
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CBT is to help patients anticipate a likely problem and increase a patients’ self-control as well as
assisting them build effective coping skills. Some techniques used in CBT include evaluating
the positive and negative consequences of an action, self-monitoring, identifying situations that
can be problematic and put one at risk for a poor outcome (Wenzel et al., 2016). Along with this
being effective in SUD, it is also a first-line treatment used in MDD (Wheeler, 2013). Research
shows skills an individual will learn through CBT will remain after successful completion of
treatment.
CBT can be used as a single therapeutic approach to treat MDD in patients with SUD or
can be used in combination with antidepressant medication therapy. CBT, as a single therapeutic
approach or in combination with medications, is a cornerstone to successful long-term outcomes
for many individuals with drug use disorders or other mental illnesses (NIDH, 2020). Protocols
like the SAMHSA Treatment Improvement protocol recommends psychotherapies such as
individual CBT or group CBT with or without adjunct antidepressant use to effectively lower
frequency of substance use and depressive symptoms (SAMHSA, 2020).
Antidepressant Therapy
Antidepressant therapy is used to treat the major depressive disorder as well as reduce the
chance of relapse. A plethora of antidepressants are used to successfully treat MDD, the most
commonly used the first line is the SSRI (Clevenger et al., 2018; Gabbard, 2014; Sadock at al.,
2014; Sadock et al., 2018). SSRIs work by inhibiting the reuptake of serotonin which then
increases serotonin activity in the body. SSRIs have fewer effects on neurotransmitters like
adrenergic, histaminergic, and cholinergic receptors than other antidepressants. This leads to far
fewer side effects from SSRIs compared to others which makes this antidepressant a more viable
option (Chu & Wadhwa, 2021; Sadock et al., 2018). According to the VA/DoD (2016) clinical
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practice guidelines a PHQ–9 score of 11 or higher calls for CBT use with or without an SSRI for
treatment. The use of CBT with an SSRI can increase the probability of a positive treatment
outcome.
Methods
Project Framework and Description
The framework used for this project was the plan-do-study-act (PDSA) model for clinical
improvement. The PDSA cycle is a quality-improvement process, that helps in introducing a new
program into a complex environment, such as an addiction facility. This works by advancing a
plan to examine the change (Plan), initiating the test (Do), perceiving and learning from the
consequences of the test (Study), and determining what modifications if need be should be made
to the test (Act) (Coury et al., 2017). In this project data was collected using a retrospective chart
review during the assessment phase. This was to determine where the gap was between the
facility’s current practice and the VA/DoD (2016) clinical practice guidelines lie. Once gaps
were identified I worked with the providers and staff to come up with a plan for the facility to
adhere to the VA/DoD (2016) clinical practice guidelines (plan phase). Suitable interventions
like the education of providers and staff, and implementation of the PHQ–9 administration
process were then implemented in the facility (do phase). Each intervention was measured
consistently throughout the project. This was to evaluate the facilities progress towards carrying
out the interventions (study). The ongoing evaluations throughout the project required me to
make adjustments to ensure the interventions were being done properly.
Provider and Staff Education
I developed education using key points from the VA/DoD (2016) clinical practice
guidelines. Education for providers was different than education given to other staff due to their
role. One-on-one interactive education was carried out with each provider on the screening,
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diagnosing, treatment, referral, and management of MDD according to the VA/DoD Clinical
Practice Guideline for the Management of Major Depressive Disorder (VA/DOD, 2016). These
sessions lasted anywhere from 20-30 minutes’ dependent on if questions were being asked on the
process. Clarification was not needed during provider education. Education on VA/DoD (2016)
clinical practice guidelines, as well as scores for the PHQ–2 and PHQ–9 , were given to staff;
This included group education seminars lasting 25-30 minutes’ dependent on questions. Staff
were educated on the entire process. During a second seminar for staff, I clarified staff only need
to attend one meeting as some staff already attended. Another change resulted in doing a seminar
at night for those staff who only work nights to accommodate their schedules. All were required
to sign in as proof of attendance.
Administration of the PHQ
The PHQ–2 was administered to every patient upon admission to the addiction facility.
The lowest score a patient can get on this questionnaire is zero and the highest is six. If a patient
had a score greater than three, it was considered to have a positive screening score. Patients who
scored positive then needed to complete the PHQ–9 .
The PHQ–9 is only administered to a patient who has a positive screening score on the
PHQ–2. The lowest score on the PHQ–9 a patient can have is zero the highest is a score of 27. A
score less than five is considered minimal depression and is not subject to any special
considerations according to the VA/DoD guidelines. Patients who scored a five or higher up
admission had to do one again in 30 days or before discharge if sooner than 30 days. The RN
puts results for PHQ under the admission section in the EHR. A clinical alert will be generated in
the system notifying the provider to review the admission note with the admitting PHQ results.
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Therapeutic Management of Depression
Patients with PHQ–9 scores from 5 – 10 will receive supportive counseling and
education from trained staff. This will be given in the form of open-ended questions staff will
learn as well as brochures given to patients on what to do if symptoms worsen. These patients
will be re-scored every month and on discharge. If at any time the patient’s score increases to 11
or greater, the patient will be started on CBT with or without the use of an SSRI and will be
scored every 30 days and upon discharge. Coordination and communication with cognitivebehavioral therapists will be implemented for effective CBT. Patients with moderate to high
scores of 11– 20 will be started on CBT with or without an SSRI as appropriate. These patients
will be scored every 30 days and upon discharge. If a patient’s subsequent score is equal to or
less than 10, the patient will be scored in 30 days while continuing the SSRI. If a patient’s score
increases during PHQ–9 monitoring, a medication adjustment may be warranted. At discharge,
if a patient was prescribed an SSRIs, they will receive a prescription for the SSRIs and a referral
to a mental health provider, as indicated. The provider will prescribe SSRI if needed.
I constructed the quality improvement project plan based primarily on the VA/DoD
Clinical Practice Guideline for the Management of Major Depressive Disorder (VA/DOD, 2016)
recommendations. This included implementation of the PHQ–9 , treatment based on scores, and
education tactics. These are the elements provided by the project leader for the planning phase:
1. Prior to project implementation, each provider will receive one-on-one interactive
education on the screening, diagnosing, treatment, referral, and management of MDD
according to the VA/DoD Clinical Practice Guideline for the Management of Major
Depressive Disorder (VA/DOD, 2016).
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2. Prior to project implementation, all staff will be educated about the guidelines and the
proper administration of the PHQ–9 .
3. Implement process for administration of the PHQ–9 .
a. Patients will be given the PHQ–2 initially; if the score is positive the PHQ–9
will be given.
b. During the initial admission assessment RN staff will complete the PHQ–9
and enter it into the EHR. Once done, a clinical alert will be generated in the
system notifying the provider to review the admission note with the PHQ–9
result.
c. For scores greater than 4, appropriate treatment will be initiated based on the
standards outlined in the VA/DoD Clinical Practice Guideline for the
Management of Major Depressive Disorder (VA/DOD, 2016).
4. The provider will implement treatment based on the PHQ–9 score and as outlined by
VA/DoD guidelines.
a. Patients with scores between 5 and 10 will receive supportive counseling and
education from trained staff. This will be given in the form of open-ended
questions from staff and patient brochures on what to do if symptoms worsen.
These patients will be rescored every month, and upon discharge. If at any
time a patient’s score increases to 11 or greater, the patient will be started on
CBT with or without SSRI and will be scored every 30 days and upon
discharge. Coordination and communication with cognitive behavioral
therapists will be implemented for effective CBT.
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b. Patients with moderate to high scores between 11 and 20 will be started on
CBT with or without an SSRI as appropriate. These patients will be scored
every 30 days, and upon discharge. If a patient’s subsequent score is less than
or equal to 10, the patient will be scored in 30 days while continuing the
SSRI. If a patient’s score increases during PHQ–9 monitoring, a medication
adjustment may be warranted.
c. At discharge, if a patient was prescribed an SSRI, they will receive a
prescription for the SSRI and referral to a mental health provider as indicated.
The provider will prescribe the SSRI if needed.
5. The objectives will be monitored via weekly review of the EHR for each patient
admitted to the addiction recovery facility during the implementation period.
Project Implementation
I began the 10-week implementation period in late January 2021 starting with the
education of providers. All were accustomed to use of the PHQ administration, so education
involved a review of the VA/DoD Clinical Practice Guideline for the Management of Major
Depressive Disorder (VA/DOD, 2016) associated with the PHQ–2 , and PHQ–9 . I also
discussed where the scores could be found in the EHR. Providers were reassured that their role in
this project was to interpret the PHQ–2 and PHQ–9 found in the EHR and then determine
which therapeutic interventions would be implemented based on the VA/DoD clinical practice
guidelines. The providers were not responsible for administering the PHQ–2 or PHQ–9
screening tools. That task fell to the staff. Each provider worked a different schedule, so meeting
with them individual based on their schedule instead of as a group seemed to be the simplest way
of completing the education process for them. This process was completed within the 1st week of
the implementation period.
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Education of the staff began the 2nd week of the implementation period. I sent a group
email to staff informing them that there were a total of four educational meetings they could
attend regarding the implementation of this project. Two of the meetings were scheduled late
morning on a weekday, one was scheduled on a weekday night, and one was scheduled on a
weekend evening. This was done to accommodate staff members’ schedules. While some staff
had heard of the PHQ–2 and PHQ–9 , not all of the staff were familiar with the assessment tools
nor were they familiar with the VA/DoD clinical practice guidelines. Therefore, all of the staff
were educated on the process of handing out the PHQ–2 and PHQ–9 assessment tools, scoring
the PHQ–2 and PHQ–9 assessment tools, and entering the results in the EHR for all new
admissions Each staff was given a copy of the PHQ- 2 (see Appendix C) and PHQ–9 screening
tool (see Appendix B). During these educational sessions, staff learned about their roles and
responsibilities in implementation of the project. RNs were instructed on when to have patients
complete the PHQ–2 and the PHQ–9 as well as where to input the results in the EHR so the
providers could see the results. MHWs and the other staff were also provided the same education
about depression and the use of the PHQ–2 and PHQ–9 as a screening tool as well as
information about how the brochures would be distributed. During one of the educational
meetings one of the staff members identified an important issue that needed to be discussed. The
staff member asked how they would prevent patients from feeling singled out since only the
patients scoring high on the PHQ–9 got brochures. This was an excellent point. To avoid this,
the staff and I decided every week I would present a patient education session on depression. The
responsibility of this presentation would transition to trained staff as the project progressed. This
presentation was for all new patients regardless of PHQ scores. After the presentation, the
brochures were handed out to all patients (see Appendix E). The patient presentations on
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depression took place on Mondays during free time lasting approximately 10 minutes from
weeks 4 to 10 of the implementation period. These presentations were voluntary for the patients,
but majority of patients attended. Although this was voluntary, patients who attended had to sign
in, so patients who did not attend were accounted for. This was to give them the brochure which,
was passed during the presentation.
New patients began receiving the PHQ–2 and PHQ–9 depression screenings at the time
of admission during week 3 of the implementation period. The staff pointed out to me that it
would be simpler for all new patients to complete the entire PHQ–9 screening tool rather than
having them complete the PHQ–2 and then take the PHQ–9 if they had a score of (provide the
cut point score here). Since the PHQ–2 were the same first two questions on the PHQ–9 , this
was something that I was amenable to implement in the project. The RNs would scan the entire
PHQ–9 into the EHR, patient who score positive on the PHQ–2 and had a score of 5 or greater
on the admitting PHQ–9 will take another PHQ–9 before discharge; This revision in the project
took place in week 4 and seemed to work more efficiently than the original plan of implementing
the PHQ–2 first.
During week 3 of the implementation period I began to monitor the RNs and providers in
person on a daily basis to ensure that the screening process and importing of results into the EHR
were done correctly. I was able to change to a more random monitoring schedule beginning in
week 4 since the providers and staff were demonstrating consistent compliance with the project
implementation plan. I also accessed to the EHR system ensure that documentation of PHQ
results were imported into the system.
Patient who scored 11 or greater on the PHQ–9 were encouraged by staff to attend all
group CBT therapy sessions. The patients’ willingness to attend most if not all of the CBT
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therapy sessions is most likely due to the rapport they had built with the staff. During week 3 of
the project implementation process, I obtained permission from providers to discuss the patients’
PHQ–2 and PHQ–9 scores during staff meetings. This helped to ensure that each patient who
scored a positive PHQ–2 or PHQ–9 would now have at least one professional staff member
from each shift that was aware of patients at risk for depression even if a professional staff
member had forgotten to check the EHR. This also helped facilitate discharge planning as the
professional staff could identify those patients close to discharge that would need to take another
PHQ–9 assessment prior to discharge.
Barriers
A barrier of this project was the possibility of noncompliance by the patients. Patient
were able to decline any part of the quality improvement project they did not want to do.
Facilitators
Facilitators of this project included the administrators, staff, providers and the CEO of the
facility. All of these individuals felt comfortable to voice their thoughts and concerns on the new
process, with the vast majority of the feedback being positive. Although some individuals needed
clarification on the implementation plane, there was no backlash regarding the proposed changes.
Ethical Considerations
After obtaining a letter of support from the CEO (see Appendix A), the project plan was
submitted and reviewed by the University of the Incarnate Word Institutional Review Board
(IRB) and was deemed to be a quality improvement project and exempt from IRB approval (see
Appendix D). I took deliberate precautions to ensure that no sensitive personal health
information was collected in order to maintain compliance with the Health Insurance Portability
and Accountability Act (HIPAA) requirements. Once the results of patients’ PHQ–2 and PHQ–9
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assessments were scanned into the EHR, the physical copies of the documents were disposed of
properly in accordance with HIPAA guidelines. All patients participated in this project on a
voluntary basis and could refuse any part of the process at any time.
Results
The first 2 weeks of the implementation process focused primarily on education of the
providers and staff. By the end of the 1st week, 100% of the providers had completed the one-onone interactive educational session with me that addressed the screening, diagnosing, treatment,
and referral of MDD according to the VA/DoD Clinical Practice Guideline for the Management
of Major Depressive Disorder (VA/DOD, 2016). I was able to meet the first anticipated outcome,
which was to have 100% of providers educated on proper usage of the PHQ–9 by the
completion of the project implementation period.
During the 1st week only one educational seminar was held and 28.8% of staff were able
to attend. During the 2nd week the amount of staff attending the educational sessions rose
exponentially. This was due to the multiple seminars held during this week. By the end of the 2nd
week 96.5% of staff had attended the required educational sessions. The remaining 3.5% of the
staff who did not attend were in the process of leaving their positions within the next 2 weeks.
By week 4 of the project implementation, those staff members who were leaving their positions
were no longer employed by the facility, which meant that 100% of the staff had attended the
required educational sessions. I was able to meet the second intended anticipated outcome which
was to have 100% of staff educated on the proper usage of the PHQ–9 by the completion of the
project implementation period.
By week 3 of the project implementation period, new patients admitted to the facility
were given the PHQ assessments and treatment was ordered in accordance with the VA/DoD
Clinical Practice Guideline for the Management of Major Depressive Disorder (VA/DOD, 2016)
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based on the level of depression diagnosed using the PHQ assessments. There were 42 patients
admitted to the facility during weeks 3 to 10 of implementation period (see Figure 1). Patients
admitted before week 3 were not included in these results as provider and staff education was not
complete. The lack of admissions in week 4 was due to inclement weather as described under
limitations. The demographical information of these 42 admissions can be found in Table 1.
Figure 1
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The vast majority of patients admitted during the project implementation period were
white males between 25 to 46 years of age. Since this was an adult facility, there were no
admissions of patients younger than 18 years of age. Interestingly enough, there were also no
admissions of patients 64 years of age or older. Insurance status was unavailable.
I met with staff and providers to discuss possible barrier and one that was brought up
multiple times was patient compliance as we were unsure how patients would react to the new
depression screenings and possible depression treatment in this facility. With this discussion I
was able to meet my seventh intended anticipated outcome which was to assembly with
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Table 1
Patient Demographics
Characteristics
Gender

Race

Age

No. (%) of Patients (n = 42)
Male

66.7%

Female

33.3%

White

85.7%

Black

11.9%

Asian

2.4%

18-24

14.3%

25-35

33.3%

36-46

33.3%

47-57

16.7%

58-64

2.4%

providers and staff to recognize and address possible barriers to 95% completion rate.
Noncompliance did not seem to be an issue as all of the individuals admitted to the facility
during the project implementation period completed the PHQ–2 or the first two questions of the
PHQ–9 . All PHQ–2 scores and PHQ–9 scores were scanned and documented in to the facilities
EHR system. I was able to meet the fourth intended anticipated outcome which was to have
100% of the completed PHQ–2 scores will be scanned and documented into the facility’s EHR
system. I was also able to meet the fifth intended anticipated outcome which was to have 100%
of the completed PHQ–9 scores will be scanned and documented into the facility’s EHR system.
Patients were more than willing to do what was need for far better treatment outcomes. Out of
the completed PHQ–2 s or the first two questions of the PHQ–9 s, 29 patients scored a 3 or
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higher and were subject to completing the entire PHQ–9 . Out of these 29 patients, 29 completed
the PHQ–9 . I was able to meet the third intended anticipated outcome, which was to have 100%
of individuals who scored positive on the PHQ–2 to complete the PHQ–9 . 27 patients scored
between 5-27, which triggered implementation of the VA/DoD Clinical Practice Guidelines for
the Management of Major Depressive Disorders (2016). All of these patients repeated the PHQ–
9 prior to discharge (See Figure 2). Those who scored 5-27 prior to discharge were evaluated
and depending on score and discharge assessment by provider were prescribed an SSRI. All
patients were referred to an outpatient mental health care facility.
Figure 1
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93% of positive patients screened attended all scheduled group CBT sessions, and 24% were
started on an SSRI along with CBT based on scores and assessment by providers. No patients
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solely had SSRIs for treatment. 76% of positive patients solely had CBT for treatment without
the use of an SSRI.
Discussion
Objective 1, which called for 100% of providers will be educated on proper usage of the
PHQ–9 by the completion of the project implementation period for was completed in the 1st
week of implementation. The project leader worked with each provider and provided education
within their schedules. Education on this outcome was based on the VA/DoD (2016) clinical
practice guidelines. Topics on what to do for suspected depression PHQ administration were
discussed. While providers were familiar with the PHQ administration process this was never
used in this facility. Assessment for the patient’s acute risk to self was also reviewed. Guidelines
state that acute risk for self-harm should be assessed upon every assessment a provider has with
the patient with suspected depression. This was the same as standards used in this facility, as all
patients are assessed for acute self-harm risk at every provider assessment. Treatment with CBT
with or without SSRI usage was also discussed. Providers were lectured on the use of SSRIs
being at their discretion based on their evaluation and PHQ scores. This had differed from what
was already in place as the PHQ was not implemented at the facility before.
Objective 2, which called for 100% of staff will be educated on proper usage of the
PHQ–9 by the completion of the project implementation period was completed by the 4th week.
I had directed education seminars on proper usage of the PHQ administration following the
VA/DoD (2016) clinical practice guidelines on all staff but one by the 2nd week. The staff
member in question was expected to be terminated in the following weeks which led to 100%
education on all staff once termination was complete. Education on depression was also included
in the seminar. While an overview of depression is not in the guidelines, I felt this was needed

DEPRESSION SCREENING UPON ADMISSION

37

for some staff like the MHWs who do not have a psychiatric background. Like outcome number
one, education on treatment for the VA/DoD (2016) clinical practice guidelines was given.
Due to education, objective 3, which called for 100% of individuals who score positive
on the PHQ–2 will complete the PHQ–9 was completed without issues. The VA/DoD (2016)
clinical practice guidelines call for patients who have scored a positive PHQ–2 to complete the
PHQ–9 . This was done by the RNs upon admission. This was done effectively to have a 100%
complete rate and adhered to guidelines with no changes. In VA/DoD (2016) clinical practice
guidelines the PHQ–9 was used as an indicator of depression severity, this did not change upon
implementation.
Objective 4, which called for 100% of the completed PHQ–2 scores to be scanned and
documented into the facility’s EHR system, was complete. Objective 5, which called for 100%
of the completed PHQ–9 scores, will be scanned, and documented into the facility’s EHR
system was complete. These two outcomes changed from what was stated in the VA/DoD (2016)
clinical practice guidelines, as the guidelines do not specify how to store completed scores of the
PHQ–2 and the PHQ–9 . An EHR electronic system is used throughout healthcare systems to
collect as well as store a patient’s important information (Ehrenstein et al., 2019). Providers were
able to see files remotely, which made response times more efficient. In this improvement
quality project, the was considered important information that can lead to better treatment
outcomes for the patient. For these reasons, it was important to have these outcomes.
Objective 6 which called for providers to adhere to the treatment standards outlined in the
VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder
(VA/DOD, 2016) to at least 95% of the time was complete. The providers' past expectations and
increased by 100%. Currently, the VA/DoD (2016) clinical practice guidelines are working on
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developing effective strategies to evaluate the intended adherence rate on clinical outcomes. This
implies that the current rate expectation for adherence is not yet 100%.
Objective 7, which called for me to assemble with providers and staff to recognize and
address possible barriers to 95% completion was complete. Barrier inefficiency was quickly
fixed to make the project run smoother for staff as well as patients. While this was not in the
VA/DoD (2016) clinical practice guidelines it was important to collaborate with staff to build
communication and increase the likelihood of successful outcomes for patients as well as the
facilities.
Many significant changes occurred for the betterment of this addiction facility during
this QI project. Patients who participated in this project most likely would not have been
assessed and treated for comorbid depression as the project site did not offer a depression
screening tool beforehand. Patients data of comorbid depression during SUD treatment from this
project showed a 26% gain from 2020’s national average of 43% in this population (NIDA,
2020). This was an interesting find as it showed a possibility of an increase in comorbid
depression in this population in the upcoming future.
Limitations
During week 4 of the project implementation period there was inclement weather, which
effected power, heating, road closures, and access to the facility. New patients were unable to
seek help at the facility due to these conditions. Furthermore, discharges from the facility were
postponed in order to ensure the safety of the patients. This effected the implementation
schedule. Another limitation to implementing this project was the coronavirus (COVID-19)
pandemic which may have limited the number of patients coming into the clinic for recovery.
COVID-19 has affected the world for more than a year and continues to result in high numbers
of deaths. Although vaccinations had started in the United States before the implementation
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period, most people in the United States had not received their vaccination which could have
stopped unvaccinated patients from seeking help for their addiction.
Recommendations
It is recommended that the facility should highly consider the continued use of the
VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder
(VA/DOD, 2016) in adults admitted for inpatient addiction recovery facility. This quality
improvement project did not require any significant modifications to the facilities current
processes in order to be effective. This made for little to no backlash from staff and providers.
The transition into the implementing phase was relatively easy for all staff involved which
benefitted patient with possible depression or depressive symptoms. Depression is often an
overlooked comorbidity in patients with SUD and can significantly affect the patient outcomes if
not addressed (SAMHSA, 2020). This project was implemented to address this issue in an
inpatient setting, but it may also apply to other inpatient populations. Geriatric and rehabilitation
inpatient facilities often have patients who are susceptible to depression (Almomani & Bani-issa,
2017), so it is important to have a depression screening process in place in order to address this
to ensure better treatment outcomes for these patients. Larger facilities may have less flexibility
in how providers and staff are educated on the clinical practice guidelines for MDD. Patients
with cognitive issues may need assessment tools like PHQ–2 and PHQ–9 to be altered to
answer depression questions.
Sustainability
The educational sessions on the use of the PHQ–2 , PHQ–9 , and the clinical practice
guidelines was the most significant change in this facility, resulting in 100% of staff and
providers receiving the education. The knowledge gleamed from these educational sessions is
foundational for sustainability of the depression screening and clinical practice guideline driven
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treatment for future patients with SUD who have a comorbidity of depression admitted to this
facility. The implementation of the PHQ–2 and PHQ–9 process has no significant cost
associated with it, so these screenings can be continued with no financial strain to the facility.
Since providers and staff at this facility are trained in CBT and medication therapies and since
these therapies are readily available at this facility, adherence to the clinical practice guidelines
for MDD can continue to be implemented in this practice. This facility already has all of the
infrastructure and resources necessary to continue implementation of this projects interventions.
Implications for Practice
Some positive outcomes expected at addiction facility treatment center are to reduce
substance abuse or achieving a substance-free life, maximize the multiple aspects of life
functioning learned at facility and to prevent or reduce the frequency and severity of relapse
(SAMHSA, 2020). Assessing all new patient admissions for depression at an adult inpatient
addiction facility gives these patients a better likelihood of a successful recovery process and can
improve patient outcomes after the inpatient recovery process is complete. This also helps
identify patients with thought of self-harm that otherwise may have been missed. Once learned
facility can take precautions to prevent a possible incident that can leave a facility liable
This approach is cost effective to the facility and patient as well. When depression is
caught early on, less invasive treatment is necessary for effective treatment. The less treatment
needed the lower the cost for the facility and patient.
Conclusion
To be effective, SUD treatment must address the individual’s drug addiction and any
associated psychological, medical, social, vocational, and legal problems (NIDA, 2018). Not
treating a patient’s comorbidities can lead to more complex clinical management, increased
healthcare cost, and far worse outcomes (Bellatreche et al., 2020). DNP essential VI which calls
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for inter-professional collaboration to improve patient and population health outcomes
(Zaccagnini & Pechacek, 2019) was a key element to the project.
The DNP-prepared nurse practitioner should serve as an effective collaborative team
leader and participant; they should participate in the works of the interprofessional team as well
as assume leadership of the team when appropriate (Zaccagnini & Pechacek, 2019).
Collaboration between the providers, staff, and myself were needed throughout the
implementation of this project to ensure its success. Without this effective collaboration this
quality improvement project may not have been as successful as it was.
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